|
Summary Information: Gemini Therapeutics Inc. Common Stock NASDAQ:GMTX |
  admin@troach.net |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically de?ned age-related macular degeneration (AMD). Gemini's lead candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH), and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant. The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies.
__The following are links to various summary and news pages for __Gemini Therapeutics Inc. Common Stock [ GMTX ]. __Note: Some Links might not have information for the company. |
|